

## **Stellar Biotechnologies Announces Appointment of New Director, David L. Hill, Ph. D.**

PORT HUENEME, CA-- May 24, 2011) - **Stellar Biotechnologies, Inc.** (TSX-V: [KLH](#)) (U.S. OTC: [SBOTF](#)) is very pleased to announce that it has appointed David L. Hill, Ph.D. as a member of its board of directors.

Stellar's new director, Dr. Hill, is a Board Certified High Complexity Laboratory Director, Board Certified Embryology Laboratory Director and member of the American Association of Bioanalysts. He is Scientific Director of the ART Reproductive Center and is currently Assistant Clinical Professor, Dept. of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA and Research Assistant IV at Cedars-Sinai Medical Center. After receiving his BS in Marine Biology at Cal Poly - San Luis Obispo, CA, Dr. Hill received his MS in Biological Sciences there then went on to a Ph.D. in Biological Sciences/Pathobiology at the University of Connecticut and post-doc Fellowship at The Dana Farber Cancer Institute (Appointment through the Department of Physiology and Biophysics, Harvard Medical School). He is listed on more than 100 peer-reviewed published papers.

Frank Oakes said, "Stellar is honored that Dr. Hill will bring his independence as well as an excellent scientific background and perspective, along with strong ties to the medical and regulatory arenas to our board. We very much look forward to working with him and gaining from his understanding."

Dr. Hill said, "Stellar Biotechnologies is an extremely interesting and innovative company, and a leader in the development of important immune diagnostics and conjugate therapeutic vaccines. It will be interesting and exciting to participate in the development of these and other novel uses for KLH. I'm honored to join such a high caliber team."

**About Stellar Biotechnologies, Inc.** (PINKSHEETS: [SBOTF](#)) (TSX-V: [KLH](#)): Stellar Biotechnologies, Inc. (TSX-V: [KLH](#)) (U.S. OTC: [SBOTF](#)) ([www.StellarBiotechnologies.com](http://www.StellarBiotechnologies.com)) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

Contact:

Darrell Brookstein

[dbrookstein@stellarbiotech.com](mailto:dbrookstein@stellarbiotech.com)

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.